Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.

ABSTRACT: Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3 clinical trials of nivolumab in mRCC.

SUBMITTER: Venur VA 

PROVIDER: S-EPMC5395273 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature